CDX-1127: Clinical Trials

4 trials of CDX-1127, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 terminated. 4 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 14Completed 2, Terminated 2
Phase 21Completed 1

Follow CDX-1127: new trials by email Literature Review of CDX-1127 trials Research Report on CDX-1127

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC
Atezolizumab 1200 MG in 20 ML Injection, Stereotactic Body Radiation Therapy, Varlilumab 3 mg/kg - Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Phase 1TerminatedRutgers, The State University of New Jersey162019-09-112026-02-05
Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma
6MHP, Montanide ISA-51, polyICLC - Melanoma
Phase 1 / Phase 2CompletedCraig L Slingluff, Jr332018-11-132024-02-06
A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)
IMA950, poly-ICLC, Varlilumab - Glioma, Malignant Glioma
Phase 1TerminatedNicholas Butowski142017-04-032024-06-14
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
CDX-1127 - CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Phase 1CompletedCelldex Therapeutics902011-10-012018-01-31

Conditions studied

Carcinoma, Non-Small-Cell Lung (2)  ·  Melanoma (2)  ·  Astrocytoma (1)  ·  Carcinoma, Renal Cell (1)  ·  Glioma (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Lung Neoplasms (1)  ·  Lymphoma, B-Cell, Marginal Zone (1)  ·  Lymphoma, Follicular (1)  ·  Lymphoma, Mantle-Cell (1)  ·  Margins of Excision (1)  ·  Oligodendroglioma (1)  ·  Ovarian Neoplasms (1)

Sponsors

Celldex Therapeutics (1)  ·  Craig L Slingluff, Jr (1)  ·  Nicholas Butowski (1)  ·  Rutgers, The State University of New Jersey (1)

Countries

United States (4)

Top investigators

Craig L Slingluff, Jr., MD (1)  ·  Hideho Okada, MD, PhD (1)  ·  Jyoti Malhotra (1)  ·  Nicholas Butowski, MD (1)  ·  Salma Jabbour (1)

Results publications

PMID 32380537

NIH funding

P30CA072720 (1), R21CA233856 (1)